MATTERHORN Trial: Imfinzi Shows Significant Survival Benefit in Gastric and GEJ Cancer Treatment

CHMP Recommends Durvalumab Combination for EU Approval in Resectable NSCLC

Nivolumab Plus Chemotherapy Demonstrates Significant Survival Benefit in Resectable NSCLC

FDA Approves Tislelizumab Plus Chemotherapy for PD-L1+ Metastatic Esophageal Cancer

KEYTRUDA Receives Priority FDA Review for Perioperative Use in ES Head and Neck Cancer

Odronextamab Gains FDA Review for Hard-to-Treat R/R Follicular Lymphoma

Enhertu Gains EMA’s CHMP Support for HER2-Low Metastatic Breast Cancer Treatment

Camizestrant Plus CDK4/6 Inhibition Boosts PFS in ESR1+, HR+/HER2– Breast Cancer

No More Doubts: CDK 4/6 inhibitor + ET as First-Line Standard for HR+ mBC

Patient Enrollment Completed in VAPOR 2 Trial for Vanquish Prostate Cancer Therapy

DNA-Based Immunotherapy IMNN-001 Promises to Improve Survival in Ovarian Cancer

New Data Confirms Darolutamide’s Safety and Efficacy in mHS Prostate Cancer

FDA Grants Priority Review to Datopotamab Deruxtecan for EGFR+ Lung Cancer

FDA Approves Innovative ADC Datroway for Metastatic HR+, HER2- Breast Cancer

FDA Approves Sotorasib and Panitumumab Combo for KRAS G12C+ Colorectal Cancer

Regulatory Approval Advances Pelareorep’s Virus Therapy for Pancreatic Cancer

FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small Cell Lung Cancer

First-Ever Obstructive Sleep Apnea Drug, Zepbound, Approved by FDA for Obesity

FDA Approves BRAFTOVI Combo as First-Line Treatment for Colorectal Cancer

Ribociclib Shows Promising Long-Term Benefits in Early Breast Cancer Treatment

AbbVie Acquires Nimble in $200 Million Deal to Strengthen Immunology Pipeline

General Inception Acquires Enable Medicine to Drive AI-Led Drug Discovery

Elevation Partners with Synaffix in $368M Deal to Advance HER3 ADC Development

Imlunestrant Shows Promising Results Alone and with Verzenio in ER+, HER2- Breast Cancer

Blenrep Combination Reduces Death Risk by 42% in Relapsed Multiple Myeloma

Breakthrough in First-Line Ovarian Cancer Treatment: KEYTRUDA and LYNPARZA

FDA Grants Accelerated Approval to Bizengri for NRG1+ Pancreatic Cancer and NSCLC

FDA Grants Breakthrough Status to Datopotamab Deruxtecan for EGFR+ Lung Cancer

Adding Blinatumomab to Chemotherapy Extends 96% DF Survival in Pediatric Leukemia

Durvalumab Granted FDA Priority Review for Muscle-Invasive Bladder Cancer Patients

FDA Approves Durvalumab as the First and Only Immunotherapy for LSSC Lung Cancer

AI-Powered PET/CT Analysis May Predict Side Effects of Immunotherapy in Lung Cancer

Roche Acquires Poseida in $1.5 Billion Deal to Advance Cell Therapy Innovation

SKYSCRAPER-01 Trial Shows Safety of Tiragolumab Plus Atezolizumab in Lung Cancer

FDA Greenlights Revumenib for Relapsed Leukemia Treatment

How the ARANOTE Trial Results Could Advance Prostate Cancer Treatment

UK Researchers Launch Groundbreaking Study to Uncover Cancer Survival Secrets

IMUNON’s Novel Immunotherapy IMNN-001 Enhances Survival in Ovarian Cancer

FDA Approves First Targeted Therapy for IDH-Mutant Glioma with Companion Diagnostic

Targeting NBR1: New Biomarker Could Predict Immunotherapy Success in Liver Cancer

AI-Powered Cancer Drug LP-184 Receives FDA Fast-Track Designation for Glioblastoma

FDA Approves VYLOY™ as a New Targeted Therapy for Advanced Gastric and GEJ Cancer

Sanofi and Orano Join Forces to Develop Novel Radioligand Therapies for Rare Cancers

FDA Approves Itovebi as First-Line Therapy for PIK3CA-Mutated Breast Cancer

Merlin Molecular Test Offers Hope for Melanoma by Reducing Unnecessary Surgeries

Bayer Expands Precision Oncology Portfolio with MOMA Therapeutics' KNOMATIC Platform

ESMO 2024: BRAFTOVI and MEKTOVI Extend Survival in Rare Mutant Lung Cancer

ESMO 2024: Novartis's Kisqali Reduces Breast Cancer Recurrence Risk by 28.5%

First Lung Cancer Vaccine Trial for BioNTech's BNT116 Launched Across 7 Countries

Next-Generation Weight Loss Therapeutic Nimacimab Enters Phase 2 Clinical Trial